Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DPC0 | ISIN: NO0010650013 | Ticker-Symbol: 7BG
Frankfurt
10.05.24
21:41 Uhr
0,011 Euro
+0,000
+0,96 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BERGENBIO ASA Chart 1 Jahr
5-Tage-Chart
BERGENBIO ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0110,01310.05.
0,0120,01210.05.

Aktuelle News zur BERGENBIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.04.BerGenBio ASA: Notice of Annual General Meeting1
30.04.BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 20231
25.04.BerGenBio ASA: New share capital registered1
17.04.BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission1
17.04.BerGenBio ASA: BerGenBio - Disclosure of shareholding-
17.04.BerGenBio ASA: BerGenBio - Disclosure of large shareholding1
16.04.BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue1
15.04.BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates1
15.04.BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue1
08.04.BerGenBio ASA: Last day of trading in warrants1
08.04.BerGenBio ASA: Mandatory notification of trade by related party to Primary Insiders1
03.04.BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue1
02.04.BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue-
02.04.BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 20251
27.03.BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue1
20.03.BerGenBio ASA: BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation435BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification BERGEN, Norway, March 20, 2024 /PRNewswire/ --...
► Artikel lesen
04.03.BERGENBIO ASA: BerGenBio to Participate in Carnegie Nordic Healthcare Seminar1
19.02.BerGenBio ASA - Approval and publication of a prospectus supplement3
14.02.BERGENBIO ASA: BerGenBio's Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum4
07.02.BerGenBio ASA: BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections342BERGEN, Norway, Feb. 7, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...
► Artikel lesen
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1